Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis

被引：14

作者：

Schjesvold, Fredrik ^{[1
,2
]}

Bringhen, Sara ^{[3
]}

G. Richardson, Paul ^{[4
]}

Perrot, Aurore ^{[5
]}

Leleu, Xavier ^{[6
,7
]}

Moreau, Philippe ^{[8
]}

A. Dimopoulos, Meletios ^{[9
]}

Hulin, Cyrille ^{[10
]}

Tekle, Christina ^{[11
]}

Foster, Meredith C. ^{[12
]}

Poole, Elizabeth M. ^{[12
]}

van de Velde, Helgi ^{[11
]}

Facon, Thierry ^{[13
]}

机构：

[1] Univ Oslo, Oslo Myeloma Ctr, Dept Haematol, Oslo Univ Hosp, Oslo, Norway

[2] Univ Oslo, KG Jebsen Ctr B Cell Malignancies, Oslo, Norway

[3] Univ Torino, Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Myeloma Unit, Turin, Italy

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Univ Toulouse, UPS, Serv Hematol, CHU Toulouse,IUCT O, Toulouse, France

[6] CHU, Serv Hematol & Therapie Cellulaire, F-1402 Poitiers, France

[7] CIC Inserm, F-1402 Poitiers, France

[8] Univ Nantes, Nantes, France

[9] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[10] Hop Haut Leveque CHU, Bordeaux, France

[11] Sanofi Oncol, Cambridge, MA USA

[12] Global Med Affairs, Sanofi Genzyme, Cambridge, MA USA

[13] Hopital Claude Huriez, Lille, France

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2021年 / 96卷 / 11期

关键词：

D O I：

10.1002/ajh.26319

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：E423 / E427

页数：5

共 50 条

[1] Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
Schjesvold, Fredrik
Richardson, Paul G.
Facon, Thierry
Alegre, Adrian
Spencer, Andrew
Jurczyszyn, Artur
Sunami, Kazutaka
Frenzel, Laurent
Min, Chang-Ki
Guillonneau, Sophie
Lin, Peggy L.
Le-Guennec, Solenn
Campana, Frank
van de Velde, Helgi
Bensfia, Samira
Bringhen, Sara
HAEMATOLOGICA, 2021, 106 (04) : 1182 - 1187
[2] Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Dimopoulos, Meletios A.
Leleu, Xavier
Moreau, Philippe
Richardson, Paul G.
Liberati, Anna Marina
Harrison, Simon J.
Prince, H. Miles
Ocio, Enrique M.
Assadourian, Sylvie
Campana, Frank
Malinge, Laure
Semiond, Dorothee
van de Velde, Helgi
Yong, Kwee
LEUKEMIA, 2021, 35 (02) : 562 - 572
[3] Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
Meletios A. Dimopoulos
Xavier Leleu
Philippe Moreau
Paul G. Richardson
Anna Marina Liberati
Simon J. Harrison
H. Miles Prince
Enrique M. Ocio
Sylvie Assadourian
Frank Campana
Laure Malinge
Dorothée Sémiond
Helgi van de Velde
Kwee Yong
Leukemia, 2021, 35 : 562 - 572
[4] Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis
Schjesvold, Fredrik H.
Richardson, Paul G.
Attal, Michel
Facon, Thierry
Alegre, Adrian
Spencer, Andrew
Jurczyszyn, Artur
Sunami, Kazutaka
Frenzel, Laurent
Min, Chang-Ki
Le-Guennec, Solenn
Campana, Frank
van de Velde, Helgi
Bensfia, Samira
Bringhen, Sara
BLOOD, 2019, 134
[5] Effect of isatuximab plus pomalidomide/dexamethasone on renal impairment in relapsed/refractory multiple myeloma: ICARIA-MM study subgroup analysis
Dimopoulos, Meletios A.
Leleu, Xavier
Moreau, Philippe
Attal, Michel
Richardson, Paul G.
Liberati, Anna Marina
Harrison, Simon J.
Prince, H. Miles
Ocio, Enrique M.
Assadourian, Sylvie
Campana, Frank
Malinge, Laure
van de Velde, Helgi
Yong, Kwee
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E254 - E254
[6] Isatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysis
Sunami, Kazutaka
Ikeda, Takashi
Huang, Shang-Yi
Wang, Ming-Chung
Koh, Youngil
Min, Chang Ki
Yeh, Su-Peng
Matsumoto, Morio
Uchiyama, Michihiro
Iyama, Satoshi
Shimazaki, Chihiro
Lee, Jae Hoon
Kim, Kihyun
Kaneko, Hitomi
Kim, Jin Seok
Lin, Tung-Liang
Campana, Frank
Tada, Keisuke
Iida, Shinsuke
Suzuki, Kenshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (08): : E751 - E761
[7] Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis
Bringhen, Sara
Pour, Ludek
Vorobyev, Vladimir
Vural, Filiz
Warzocha, Krzysztof
Benboubker, Lotfi
Koh, Youngil
Maisnar, Vladimir
Karlin, Lionel
Pavic, Michel
Campana, Frank
Le Guennec, Solenn
Menas, Fatima
van de Velde, Helgi
Richardson, Paul G.
LEUKEMIA RESEARCH, 2021, 104
[8] Efficacy and safety of isatuximab plus pomalidomide and dexamethasone in East Asian patients with relapsed/refractory multiple myeloma: A subgroup analysis of ICARIA-MM study
Ikeda, T.
Sunami, K.
Huang, S-Y.
Wang, M-C.
Koh, Y. I.
Min, C. G.
Yeh, S-P.
Matsumoto, M.
Uchiyama, M.
Iyama, S.
Shimazaki, C.
Lee, J. H.
Kim, K. H.
Kaneko, H.
Kim, J. S.
Lin, T-L.
Campana, F.
Tada, K.
Iida, S.
Suzuki, K.
ANNALS OF ONCOLOGY, 2019, 30
[9] Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis (vol 106, pg 1182, 2021)
Schjesvold, Fredrik
Richardson, Paul G.
Facon, Thierry
Alegre, Adriaprimen
Spencer, Andrew
Jurczyszyn, Artur
Sunami, Kazutaka
Frenzel, Laurent
Min, Chang-Ki
Guillonneau, Sophie
Lin, Peggy L.
Le-Guennec, Solenn
Campana, Frank
van de Velde, Helgi
Bensfia, Samira
Bringhen, Sara
HAEMATOLOGICA, 2022, 107 (03) : 774 - 775
[10] Efficacy of isatuximab/pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA-MM high-risk cytogenetics subgroup analysis
Harrison, Simon J.
Richardson, Paul G.
Alegre, Adrian
Simpson, David
Wang, Ming Chung
Spencer, Andrew
Delimpasi, Sossana
Hulin, Cyrille
Sunami, Kazutaka
Facon, Thierry
Vlummens, Philip
Yong, Kwee
Campana, Frank
Inchauspe, Marlene
Mace, Sandrine
Risse, Marie-Laure
van de Velde, Helgi
Attal, Michel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E33 - E33

← 1 2 3 4 5 →